Risk Review
Dr. Farag reviews your personal and family history, current screenings, and prevention goals to confirm Cancerguard is appropriate.
Cancerguard Multi-Cancer Detection Test in Fort Myers, FL
Multi-Cancer Blood Test
Your Cancerguard Multi-Cancer Detection Test at a glance:
Single Blood Draw:10-15 minutes
Multi-Cancer Signal Detection:Across many cancer types
cfDNA Methylation Analysis:Genome-wide patterns
Results Turnaround:Approximately 2-3 weeks
The Early Detection Gap
Why Standard Screening Is Not Enough
Recommended cancer screenings (mammography, colonoscopy, low-dose CT for high-risk smokers, cervical and prostate testing) cover only a small subset of cancers. The majority of cancer types have no routine screening test at all, so they are typically detected only after symptoms appear, when the disease has often progressed beyond its earliest, most treatable stage. For many adults with family history, environmental exposures, or simply a desire to be proactive, this leaves a significant blind spot in their preventive care.
Cancerguard at RegalMed Clinic adds a layer of multi-cancer signal detection on top of your standard screenings. The test analyzes circulating cell-free DNA (cfDNA) in a single blood sample for methylation patterns associated with many cancer types. Dr. Farag uses Cancerguard results as one data point in a personalized longevity and prevention plan, integrating findings with your medical history, family risk profile, and other diagnostic testing to guide next-step evaluation when a signal is identified.
What Is the Cancerguard Multi-Cancer Detection Test?
cfDNA Methylation and Machine Learning
Cancerguard is a multi-cancer early detection (MCED) blood test offered as a clinical laboratory-developed test by Adela. From a single venous blood draw, the lab isolates circulating cell-free DNA (cfDNA), the small DNA fragments shed into the bloodstream by both healthy and abnormal cells. Cancerguard analyzes these fragments for methylation patterns, chemical marks on DNA that differ between healthy tissue and tumor tissue.
Proprietary machine learning algorithms then evaluate genome-wide methylation signatures to identify whether a cancer signal is present and, when detected, to suggest the most likely tissue or organ of origin. Cancerguard is designed to screen for cancer signals across many cancer types in a single test. It is intended to complement, not replace, age-appropriate standard screenings such as mammography, colonoscopy, and low-dose CT.
Treatment Timeline
Blood Draw
Single venipuncture, 10-15 minutes
Lab Processing
Approximately 2-3 weeks
Results Review
Detailed consultation with Dr. Farag
Recommended Cadence
Annual, alongside standard screening
Benefits of Cancerguard Testing
Proactive, Data-Driven Screening
- 01
Single Blood Draw
One venipuncture screens for cancer signals across many cancer types
- 02
Beyond Standard Screening
Designed to help detect cancers that have no routine screening test
- 03
Methylation-Based Approach
Uses genome-wide cfDNA methylation, a strong tumor-specific signal
- 04
Tissue of Origin Guidance
Helps direct follow-up imaging or specialist evaluation when signal is found
- 05
Minimal Invasiveness
Standard blood draw with no radiation, contrast, or procedural risk
- 06
Physician-Led Interpretation
Dr. Farag integrates results into a personalized prevention plan
Cancerguard vs Alternatives
Compare Your Options
| Treatment | Mechanism | Time | Results | Duration | Downtime | Best For |
|---|---|---|---|---|---|---|
| Cancerguard Multi-Cancer Detection | cfDNA methylation analysis with machine learning across many cancer types | 10-15 min draw | 2-3 weeks | Annual screening cadence | None | Broad multi-cancer signal detection alongside standard screening |
| Galleri Multi-Cancer Early Detection | cfDNA methylation analysis screening for cancer signals across 50+ cancer types | 10-15 min draw | Approximately 2 weeks | Annual screening cadence | None | Adults 50+ or with elevated cancer risk seeking broad MCED screening |
| Standard Cancer Screening (mammogram, colonoscopy, low-dose CT) | Imaging and procedural screening for specific organ-based cancers | Varies by test | Days to weeks | Per guideline schedule | Minimal to moderate (colonoscopy) | Established, guideline-recommended screening for specific cancer types |
Who Is a Good Candidate for Cancerguard?
Candidacy Assessment
Cancerguard is intended for adults who want to add a layer of multi-cancer signal screening to their preventive care, particularly those at average to elevated risk who are also up to date on their guideline-recommended screenings.
Ideal Candidates for Cancerguard Testing
- Adults age 50 and older who are also up to date on standard screenings
- Adults with a personal or family history of cancer or known genetic risk factors
- Individuals with significant environmental, occupational, or lifestyle exposures
- Patients pursuing proactive, data-driven longevity and prevention care
- Patients seeking screening for cancer types that have no routine screening test
Who Should Wait or Discuss First
- Patients currently being evaluated for, or under treatment for, a known cancer
- Pregnant patients (cfDNA from pregnancy can interfere with results)
- Patients who have had a recent solid organ or stem cell transplant
- Patients who would not pursue follow-up diagnostic workup if a signal were detected
Dr. Farag will review your medical history, family history, and prevention goals during consultation to determine whether Cancerguard is a good fit and how it complements your existing screening plan.
What Happens During Your Test
Blood Draw
A single venipuncture collects the blood sample, taking only 10-15 minutes with no fasting typically required.
Lab Analysis
The Adela laboratory performs cfDNA methylation analysis with proprietary machine learning over approximately 2-3 weeks.
Results Consultation
Dr. Farag reviews your report in detail, explaining whether a cancer signal was detected and, if so, the suggested tissue of origin.
Action Plan
If no signal is detected, screening continues on schedule. If a signal is found, Dr. Farag coordinates diagnostic follow-up and specialist referrals.
Side Effects & Considerations
What to Know
Cancerguard testing involves a standard blood draw with minimal physical risk. The most important considerations are how to interpret results and how the test fits into your overall screening plan.
Common Side Effects from the Blood Draw
- Minor bruising or tenderness at the venipuncture site that resolves within 1-2 days
- Brief lightheadedness during or immediately after the draw (uncommon)
Important Considerations About Results
- Cancerguard is a screening test designed to detect cancer signals; it is not a diagnostic test and does not confirm or rule out cancer on its own
- A "signal detected" result requires diagnostic follow-up (typically imaging and possibly biopsy) to determine whether cancer is actually present
- A "no signal detected" result does not guarantee the absence of cancer; standard age-appropriate screenings should continue
- False positives and false negatives are possible with any screening test, including MCED tests
- Cancerguard is offered as a clinical laboratory-developed test and is not a substitute for guideline-recommended screening
Dr. Farag interprets every result in the context of your full medical and family history and clearly explains what the findings mean for your prevention plan.
Cancerguard Cost in Fort Myers
Transparent Screening Pricing
Cancerguard multi-cancer detection testing at RegalMed Clinic is a strategic investment in proactive cancer screening, particularly for adults who want to look beyond the limited set of cancers covered by standard guideline tests.
Pricing Overview
Cancerguard testing typically ranges from approximately $900-$1,500 depending on current laboratory pricing and any applicable patient programs. This includes the blood draw, laboratory analysis, and a thorough results review with Dr. Farag.
What's Included
- Initial consultation and personal and family risk review
- Blood draw and specimen processing
- cfDNA methylation analysis with multi-cancer signal detection
- Tissue of origin guidance when a signal is detected
- Follow-up consultation and personalized prevention plan
- Coordination of any indicated diagnostic workup
Insurance & Payment
Multi-cancer early detection tests are typically not covered by standard insurance plans because they are considered emerging screening technology. RegalMed Clinic accepts major credit cards and can provide documentation for HSA/FSA reimbursement when applicable. Contact our Fort Myers office at (239) 395-2434 for current pricing details and patient program availability.
Why Choose RegalMed Clinic
Fort Myers Cancer Screening and Longevity Medicine
Physician-Led Screening Plan
Dr. Farag personally reviews candidacy, results, and next steps
Multi-Test MCED Options
Regal offers Cancerguard alongside Galleri and Shield to match the right test to your risk
Integrated Prevention Care
Results combined with diagnostics, lifestyle, and longevity protocols
Clear Follow-Up Pathway
Coordinated imaging and specialist referrals when a signal is detected
Related Services
Cancer Screening
Advanced Diagnostic Testing
Regenerative Medicine
Cancerguard FAQ
Answers to Your Questions
01 Does Cancerguard diagnose cancer?
No. Cancerguard is a screening test designed to detect cancer signals from cfDNA in a blood sample. It does not diagnose cancer. If a signal is detected, Dr. Farag will coordinate diagnostic follow-up, typically imaging and, when needed, a biopsy, to determine whether cancer is actually present.
02 How is Cancerguard different from Galleri and Shield?
All three are blood-based tests that analyze cfDNA, but they use different analytical approaches and target different cancer panels. Cancerguard (Adela) and Galleri (Grail) are both multi-cancer early detection tests using methylation analysis with proprietary machine learning. Shield (Guardant) is focused on colorectal cancer screening. Dr. Farag helps you choose the test that best matches your risk profile and prevention goals.
03 Is Cancerguard FDA approved?
Cancerguard is offered as a clinical laboratory-developed test (LDT) performed in a CLIA-certified laboratory. As of late 2025, it is not FDA-approved as a screening device. Dr. Farag will explain the regulatory status, current evidence, and how Cancerguard fits alongside FDA-cleared screening tools as part of your overall plan.
04 Does Cancerguard replace mammograms, colonoscopies, or other standard screenings?
No. Cancerguard is designed to complement, not replace, age-appropriate guideline screenings. Mammography, colonoscopy, low-dose CT for eligible smokers, cervical screening, and prostate evaluation should continue as recommended by current guidelines. Cancerguard adds an additional layer of multi-cancer signal screening.
05 What does a 'no signal detected' result mean?
A 'no signal detected' result means that no cancer signal was identified in your blood sample at the time of testing. It does not guarantee the absence of cancer, and standard screenings remain important. Dr. Farag will recommend an appropriate retest cadence, typically annual, and continue your routine prevention plan.
06 What happens if a cancer signal is detected?
Dr. Farag will discuss the report with you in detail, including the suggested tissue of origin. She will then coordinate diagnostic follow-up, which may include targeted imaging (MRI, CT, or ultrasound), specialist referrals, and, if indicated, a biopsy. The goal is to clarify what the signal represents and act on it promptly.
07 Do I need to fast before the blood draw?
Fasting is not typically required for Cancerguard. Dr. Farag will provide specific preparation instructions when you schedule, and may coordinate the draw with any other lab work that does require fasting.
08 How often should I repeat Cancerguard?
Annual testing is the most common cadence for adults pursuing ongoing multi-cancer signal screening, but the right interval depends on your age, personal and family history, and prior results. Dr. Farag will recommend a schedule tailored to your individual risk profile.
Location15750 New Hampshire Ct, STE D
Fort Myers, FL, 33908
Fort Myers, FL, 33908
Phone(239) 395-2434
Schedule Your Cancerguard - Multi-Cancer Detection Test Consultation
References
- PubMed (PMID: 33417141) - Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA (Liu MC et al., Annals of Oncology, 2020).
- PubMed (PMID: 34176935) - Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set (Klein EA et al., Annals of Oncology, 2021).
- PubMed (PMID: 36055464) - The PATHFINDER study: assessment of the implementation of a multi-cancer early detection test in a clinical setting (Schrag D et al.).
- PubMed (PMID: 30894373) - Genome-wide cell-free DNA fragmentation in patients with cancer (Cristiano S et al., Nature, 2019).
- PubMed (PMID: 29348365) - Detection and localization of surgically resectable cancers with a multi-analyte blood test (Cohen JD et al., Science, 2018).
- PubMed (PMID: 31269198) - DNA methylation-based classification of central nervous system tumours and broader applications of methylation profiling in cancer detection (Capper D et al., Nature, 2018).
- PubMed (PMID: 35092596) - Machine learning approaches for early cancer detection from circulating tumor DNA: opportunities, challenges, and clinical translation.